40.00
前日終値:
$39.65
開ける:
$39.64
24時間の取引高:
529.14K
Relative Volume:
0.91
時価総額:
$2.32B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
3.5211
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+22.29%
6か月 パフォーマンス:
+16.08%
1年 パフォーマンス:
-17.53%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AGIO
Agios Pharmaceuticals Inc
|
40.00 | 2.30B | 32.87M | 674.31M | -330.11M | 11.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-24 | 開始されました | H.C. Wainwright | Buy |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
2023-02-03 | 開始されました | Piper Sandler | Overweight |
2022-11-17 | アップグレード | Goldman | Sell → Neutral |
2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-12-03 | 開始されました | BofA Securities | Buy |
2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
2021-07-01 | 開始されました | Raymond James | Mkt Perform |
2021-06-10 | 開始されました | H.C. Wainwright | Buy |
2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-05-23 | 再開されました | Goldman | Neutral |
2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
2018-05-23 | 開始されました | Citigroup | Buy |
2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
2018-02-15 | 繰り返されました | Needham | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-08-10 | 繰り返されました | Needham | Buy |
2017-08-08 | 繰り返されました | SunTrust | Buy |
2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2017-06-26 | ダウングレード | Janney | Buy → Neutral |
2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
2016-10-24 | 開始されました | Needham | Buy |
2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com
Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
What drives Agios Pharmaceuticals Inc. stock priceTriple-digit returns - Autocar Professional
BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockFree Consultation - jammulinksnews.com
Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus
Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser
Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser
Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser
Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq
Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan
Public market insider buying at Extendicare (EXE) - The Globe and Mail
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World
FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Trend Tracker for (AGIO) - news.stocktradersdaily.com
Agios pharma chief medical officer Gheuens sells $452,601 in stock By Investing.com - Investing.com Canada
Agios Pharmaceuticals Inc. (AGIO) Shares Soar 7.69% on FDA Designation - AInvest
Agios Pharma Appoints Dr. Jay Backstrom as Director - The Globe and Mail
Agios Pharmaceuticals appoints Jay Backstrom to board of directors By Investing.com - Investing.com South Africa
Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors. - AInvest
Agios Appoints Dr. Jay Backstrom To Board - citybiz
Agios appoints Dr. Jay Backstrom to board of directors - MarketScreener
Agios Appoints Dr. Jay Backstrom to Board of Directors - The Manila Times
Agios Pharmaceuticals Appoints Dr. Jay Backstrom to Board of Directors - Quiver Quantitative
Agios Appoints Dr. Jay Backstrom to Board of Directors | AGIO St - GuruFocus
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Defensive Index - MarketScreener
Agios pharma chief legal officer Burns sells $93k in stock - Investing.com
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN
Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Scadden David | Director |
Jul 10 '25 |
Sale |
40.00 |
1,400 |
56,000 |
17,603 |
Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Option Exercise |
25.01 |
11,914 |
297,969 |
73,185 |
Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Sale |
37.99 |
11,914 |
452,601 |
61,271 |
大文字化:
|
ボリューム (24 時間):